Novocure Reports First Quarter 2021 Financial Results and Provides Company Update

Quarterly net revenues of $134.7 million with 80% gross margin Interim analysis for phase 3 pivotal LUNAR trial in non-small cell lung cancer concluded with favorable recommendation to continue the trial with reduced sample size ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended March 31, 2021, highlighting continued commercial …

Novocure Announces FDA IDE Approval and Steering Committee for KEYNOTE-B36 Trial Evaluating Tumor Treating Fields Together with Pembrolizumab in Non-Small Cell Lung Cancer

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced that the U.S. Food and Drug Administration (FDA) has approved its investigational device exemption (IDE) application to initiate the KEYNOTE-B36 trial, conducted in collaboration with MSD (Merck & Co., Inc., Kenilworth, NJ, USA). Novocure also announced the members of its scientific steering committee who will provide expert …

Novocure Announces Update on Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-Small Cell Lung Cancer

Pre-specified interim analysis concluded with favorable recommendation to continue the LUNAR trial DMC stated accrual to 534 patients is likely unnecessary and possibly unethical for patients randomized to control arm and recommended a shortened trial ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced an update regarding its phase 3 pivotal LUNAR trial of Tumor Treating …

Novocure Announces 26 Presentations at American Association for Cancer Research (AACR) Annual Meeting 2021 Suggesting Broad Applicability of Tumor Treating Fields

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced 26 presentations on Tumor Treating Fields suggesting broad applicability of Tumor Treating Fields at the American Association for Cancer Research (AACR) Annual Meeting 2021, held virtually from April 10 to April 15, 2021. Research spanning seven solid tumor types confirms the anti-mitotic effect of Tumor Treating Fields …

Novocure to Report First Quarter 2021 Financial Results

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that it will report financial results for the first quarter 2021 on Thursday, April 29, 2021, before the U.S. financial markets open. Novocure’s management will host a conference call and webcast to discuss its financial results for the three months ended March 31, 2021, at 8 a.m. …

Novocure Announces Addition to Its Board of Directors

Timothy J. Scannell, President and Chief Operating Officer of Stryker Corporation, elected to board of directors ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) has announced an addition to its board of directors. Timothy J. Scannell, an experienced executive leader, was elected to Novocure’s board on Feb. 5. “We are extremely pleased to welcome Tim to our …

Novocure to Participate in the 39th Annual J.P. Morgan Virtual Healthcare Conference

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) will participate virtually in the 39th Annual J.P. Morgan Healthcare Conference on January 11 through January 14, 2021. William Doyle, Novocure’s Executive Chairman, will speak on behalf of the company and address questions from analysts at 8:20 a.m. EST on January 12, 2021. Management will also participate in one-on-one …

Novocure Announces National Reimbursement in Switzerland for Optune® in Combination With Temozolomide for the Treatment of Newly Diagnosed Glioblastoma

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ:NVCR) announced today that the Swiss Federal Office of Public Health (BAG) has added Optune in combination with temozolomide to the List of Remedies and Equipment (MiGeL) for the treatment of patients with newly diagnosed glioblastoma (GBM), effective April 1, 2021. The List of Remedies and Equipment defines which medical devices …